肺抑瘤合剂对Ⅲ_B、Ⅳ期肺腺癌疗效的临床观察和对血清VEGF的影响.pdf

提 要 目的：通过肺抑瘤合剂对ⅢB、Ⅳ期肺腺癌合并胸腔积液患者的临床疗效观察， 探讨肺抑瘤合剂治疗肺癌的作用机制，为中医药治疗Ⅲ、Ⅳ期肺腺癌患者提供理论依 据，并研究中医药对于胸腔积液治疗的可行性。方法：将符合纳入标准的90例ⅢB、 Ⅳ期肺腺癌并伴有胸腔积液患者随机分为三组，其中中药组30例，中药加免疫支持组 30例，化疗加免疫支持组30例。观察主症（咳嗽、咯血、发热、胸痛、气急等）的变 化、病灶变化、生存期比较、生活状态KPS评分比较、肿瘤标记物的参数变化、血清 VEGF的变化。结果：结果显示，三组治疗后有效率比较有统计学差异（P＜0.05），肺 抑瘤合剂加免疫支持组有效率优于其他两组（P＜0.05），纯中药组疗效优于化疗加免 疫支持组（P＜0.05）；三组治疗后细胞因子水平变化较治疗前有统计学差异（P＜ 0.05），血清VEGF都有所下降（P＜0.05）。结论： 肺抑瘤合剂可以显著减轻患者的主 要症状，提升了肺癌患者的生存质量，延长了患者生存时间，减轻了患者的经济负担， 为中医药治疗肺癌提供了行之有效的方法。 关键词 肺抑瘤合剂；ⅢB、Ⅳ期肺腺癌； 伴有胸腔积液 Clinical Research and effect on levels of serum VEGF and ⅢB、Ⅳ Lung adenocarcinoma of traditional Chinese medicine Speciality: The research of Lung Disease. Medicine of TCM Author:Chen Xiangjun Tutor:Professor Zheng Xin Abstract Objective: Through the lung tumor suppressor mixture on ⅢB、Ⅳand efficacy in Lung adenocarcinoma patients with pleural effusion to verify Chinese medicine treatment has significant effects ，to provide a theoretical basis for Chinese medicine treatment III, IV lung adenocarcinoma patients, and to study the feasibility of Chinese medicine for the treatment of pleural effusion 。 Methods: The selected 90 patients with adenocarcinoma of the lung were randomly divided into three groups, of which 30 cases of Chinese medicine, Chinese medicine plus immune support group 30 cases, chemotherapy group 30 patients (excluding out of the process of experimental chemotherapy patients) to observe the main symptoms ( cough、 hemoptysis 、 fever 、 chest pain 、 shortness of breath 、 etc 。) changes, the changes in lesions, daily life, K • S score of comparison, the parameters of change in tumor markers, immune indicators of T cell subsets, T lymphocyte transformation rate of change, health expenses 。 Result: